Incannex Healthcare Ltd IXHL is soaring Tuesday on abnormally-high volume. The stock has been extremely volatile since the company released a preliminary analysis of data from its phase 2 clinical trial investigating its novel cannabinoid combination product, IHL-42X, for the treatment of obstructive sleep apnoea.
Related Link: Incannex Clinical Trial Shows Notable Reduction In The Apnoea Hypopnoea Index With Novel Cannabinoid Product
Incannex's average session volume is 5,768 over a 100-day period, according to data from Benzinga Pro. Tuesday's trading volume has already exceeded 325,000 at publication time.
Incannex is a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs.
IXHL Price Action: Icannex shares are making new 52-week highs after being halted several times during Tuesday's trading session.
The stock was up 210% at $71 at time of publication.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!